9 picks this Month:
-
Cardiovascular risk in AD: inflammation, lifestyle, or both?
Sanabria-de la Torre R et al. Factors in Adults with Atopic Dermatitis: A Cross-sectional Study. Acta Derm Venereol. 2026;106:adv-2026-0452.
➜ DOI: 10.2340/actadv.v106.adv-2026-0452.
Why it matters:
The association between atopic dermatitis (AD) and cardiovascular disease remains debated, particularly regarding the respective roles of chronic inflammation and modifiable lifestyle factors. This Spanish case-control study compared 50 adults with predominantly moderate-to-severe AD with 50 age- and sex-matched controls using anthropometric, lifestyle, hemodynamic and laboratory measures. Patients with AD had a higher BMI, lower physical activity and, strikingly in a Mediterranean setting, significantly poorer adherence to the Mediterranean diet. The cardiovascular signal was also notable: patients had higher peripheral and central blood pressure, with most differences persisting after adjustment for BMI and education, while CRP remained significantly elevated after adjustment. In the smaller subgroup eligible for PREVENT risk estimation, 10-year predicted cardiovascular risk was higher in AD.
Context and caution:
The study is small, single-center and cross-sectional, includes mainly patients with severe disease, and involved multiple exploratory comparisons without formal correction. It therefore cannot determine whether cardiovascular risk is driven primarily by AD-related inflammation, by obesity and lifestyle, or by an interaction between these factors.
Bottom line:
This study does not settle the cardiovascular-risk debate in AD, but it adds an interesting dimension. Even in southern Spain, where a Mediterranean dietary pattern is readily accessible, some selected patients with AD had poorer diet adherence and less physical activity together with a less favorable cardiovascular profile. The findings support looking beyond the skin in severe AD and considering both disease control and modifiable cardiovascular risk factors as part of long-term care.
-
Do stable patients on biologics really need to travel for every follow-up?
Henckens NFT et al. Patients’ and clinicians’ perspectives on telemedicine to monitor patients on systemic treatment for psoriasis or atopic dermatitis — a mixed methods study. J Dermatolog Treat. 2026;37:2703354.
➜ DOI: 10.1080/09546634.2026.2703354
Why it matters:
In this Dutch mixed-methods study, 162 patients receiving systemic treatment for psoriasis or AD and 152 dermatological care providers were surveyed. Nearly half of the patients had AD, and most were receiving biologics; a smaller subgroup received JAK inhibitors. Both patients and clinicians were broadly favorable toward telemedicine when disease was stable. Time and travel costs were major advantages for patients, and even in the relatively compact Netherlands the median round-trip distance was about 40 km by car/taxi and 51 km by public transport. The potential relevance may therefore be even greater in larger countries.
Context and caution:
Telemedicine was not viewed as a substitute for clinical assessment when disease became unstable, new symptoms or adverse events appeared, or treatment needed to be initiated or changed. The study measures preferences and feasibility rather than demonstrating clinical equivalence or safety of a particular follow-up schedule, and it combines psoriasis and AD. Interestingly, the interviewed clinicians favored at least one face-to-face visit per year, although no formal guideline supported that interval.
Bottom line:
In the era of effective long-term systemic therapies, the relevant question may no longer be whether telemedicine can replace clinic visits, but which components of follow-up truly require physical attendance. For stable AD, separating drug renewal and routine monitoring from the need for a comprehensive face-to-face examination could make care more patient-centered, accessible and sustainable—particularly where specialist care is geographically distant.
-
When itch feeds delusion: an unexpected dupilumab signal
Fontaine D et al. JAAD International, 2026. Singh N, Conner A, Nahmias Z. JAAD International, 2024.
➜ DOI: 10.1016/j.jdin.2026.05.027; 10.1016/j.jdin.2024.01.001
Why it matters:
An intriguing psychodermatology signal is emerging around dupilumab in delusions of parasitosis/delusional infestation. Singh et al. initially reported symptomatic improvement in 9 of 11 patients treated with dupilumab. The new Dartmouth series adds five patients: three had partial and two complete responses within 3–12 months, despite the absence of concomitant antipsychotic treatment.
Context and caution:
These uncontrolled observations do not establish that dupilumab treats the delusional disorder itself. Importantly, four of the five new patients were considered to have primary delusions of parasitosis, whereas only one had severe poorly controlled AD, suggesting that improvement may not simply reflect control of eczema. The authors raise the provocative hypothesis that blocking IL-4Rα signalling could reduce abnormal cutaneous sensations through neuroimmune effects on sensory neurons, thereby interrupting the sensation–attention–delusion cycle. Small numbers, retrospective selection, concomitant treatments and the absence of controls make this hypothesis far from proven.
Bottom line:
Beyond an unusual off-label therapeutic observation, these reports highlight how the type-2 inflammation–sensory neuron–itch axis, increasingly central to AD biology, may also influence perception and behaviour. An unexpected bridge between atopic dermatitis, chronic itch and psychodermatology worth watching.
-
AD and One Health from the veterinary side: pets as patients and environmental sentinels
Marsella R. Journal of the American Veterinary Medical Association, 2026.
Related One Health review:
Minić-Pantić D, Abela B, Lehtimäki J, et al. Examining atopic dermatitis through the One Health concept lens. Allergy. 2026;81:345–357➜ DOI: 10.2460/javma.26.06.0472
Why it matters:
This review examines how urbanization, pollution, dietary and chemical exposures, loss of microbial diversity and climate change may contribute to allergic skin disease in companion animals. Many of these mechanisms overlap with those discussed in our recent Allergy review on AD through the One Health lens, which is cited by Marsella. The distinctive contribution here is the veterinary perspective: animal health is placed at the centre, with dogs viewed not only as comparative models of human AD but as patients sharing our environment and potentially acting as sentinels of the household exposome.
Context and caution:
The article develops several environmental exposures in greater veterinary detail, including indoor particulate pollution, microplastics, PFAS, food processing, bisphenols, heavy metals, heat and wildfire smoke. However, the strength of evidence varies considerably. Some associations are supported by canine data—for example, higher indoor PM2.5 exposure and greater skin permeability in dogs with AD—whereas other proposed mechanisms are extrapolated from human or experimental studies.
Bottom line:
Companion animals are themselves affected by the same urban, chemical and climatic changes, and their disease may provide an additional window into shared environmental exposures. This veterinary-centred view strengthens the concept of the dog as both an affected patient and a sentinel of our common exposome.
-
Beyond the epidermal barrier: does successful AD treatment remodel the basement membrane?
Nørgaard Have MK et al. Journal of Investigative Dermatology, 2026.
➜ DOI: 10.1016/j.jid.2026.08.001
Why it matters:
The epidermal barrier is central to AD biology, but the dermal–epidermal junction and basement membrane are much less often considered as dynamic components of disease. This exploratory study measured circulating markers of type IV, VII and XXII collagen turnover in two longitudinal AD cohorts treated with dupilumab, tralokinumab, abrocitinib or baricitinib. In patients receiving JAK inhibitors, markers of type IV collagen degradation (C4M) and type XXII collagen turnover (PRO-C22) decreased after treatment, while responders to IL-4/IL-13 blockade showed reduced type VII collagen maturation (PRO-C7). C4M also correlated moderately with EASI.
Context and caution:
These findings suggest that improvement in AD may involve measurable changes in extracellular-matrix turnover at the basement membrane, potentially reflecting restoration of tissue integrity in parallel with reduced inflammation. The intriguing suggestion of faster remodeling with JAK inhibitors should, however, be interpreted cautiously. The cohorts were small, sample types and follow-up schedules differed, and the study was not designed for direct comparison between JAK inhibitors and biologics. The authors also note that 12–16 weeks may be too short to fully assess structural effects of biologic treatment.
Bottom line:
This study extends the concept of barrier repair beyond the stratum corneum and keratinocyte differentiation to the dermal–epidermal junction and extracellular matrix. Whether basement-membrane biomarkers can eventually distinguish simple suppression of inflammation from deeper tissue normalization—and perhaps contribute to longer-term Treat-to-Target or disease-modification strategies—will require validation in larger, harmonized longitudinal studies.
-
Can prenatal pollution leave an immune memory of atopic dermatitis?
Yang DY et al. Nature Communications, 2026.
➜ DOI: 10.1038/s41467-026-76298-6
Why it matters:
Epidemiological studies have repeatedly linked air pollution with childhood AD, but the biological bridge from prenatal exposure to later disease has remained uncertain. This study links first-trimester PM2.5 exposure with increased early-childhood AD risk and identifies an intriguing potential mechanism: hypomethylation and persistent overexpression of FCER1G in fetal macrophages. Integrative epigenomic, transcriptomic and single-cell analyses suggest that this program can persist across development and reappear in M2 macrophages in AD skin and blood. Functional experiments further connected FCER1G-associated networks with oxidative stress and type-2 inflammatory pathways.
Context and caution:
This goes beyond another epidemiological pollution association by proposing a form of developmental immune programming linking the prenatal exposome to later AD. However, association between maternal PM2.5 exposure and childhood AD does not by itself establish causality in humans; the multi-omics and functional experiments provide mechanistic plausibility rather than proof that this pathway explains pollution-associated AD in individual children.
Bottom line:
The study adds an important dimension to the exposome concept: environmental influences on AD may begin before the skin barrier has even encountered the external environment. If replicated, persistent epigenetic programming of fetal immune cells could help explain how relatively early and transient environmental exposures influence susceptibility to inflammatory disease years later.
-
How does damaged skin talk to T cells? A lipid-sensing pathway in AD
Babu RO et al. British Journal of Dermatology, 2026.
➜ DOI: 10.1093/bjd/ljag391
Why it matters:
Barrier dysfunction is central to AD, but how immune cells actually sense that the barrier has been damaged is less well understood. Combining human skin allergen challenge, single-cell and spatial transcriptomics and functional immunology, this study identifies persistent activated CD1a-positive dendritic cells in subepidermal niches of lesional AD skin. These cells produce CCL17/CCL22, colocalize with Th2-cell populations and express neutral sphingomyelinase, which modifies sphingomyelin metabolism in a way that promotes CD1a-autoreactive T-cell responses.
Context and caution:
The work provides an attractive mechanistic link between lipid metabolism, barrier injury and type-2 immunity, suggesting that altered endogenous lipids may function as signals of tissue damage rather than merely reflecting defective barrier composition. The study is mechanistically sophisticated and based on human tissue, although the pathway still needs to be positioned quantitatively within the many immune circuits operating in AD.
Bottom line:
The epidermal barrier is not simply a wall that becomes leaky in AD. Its altered lipid environment may itself provide information to the immune system. CD1a-mediated recognition of lipid changes offers an intriguing mechanism by which chronic barrier disruption could perpetuate Th2 inflammation.
-
Does Staphylococcus aureus evolve inside atopic skin?
Uyar E, Jamet A. Trends in Microbiology, 2026.
➜ DOI: 10.1016/j.tim.2026.08.015
Why it matters:
Rather than asking only why Staphylococcus aureus colonizes AD skin, this short perspective asks a more unusual question: what does chronic residence in diseased skin do to the bacterium itself? The authors propose that chronic inflammatory skin diseases such as AD can be viewed as natural experiments in within-host microbial evolution. Recurrent genetic variants arising independently in S. aureus isolates from different patients may represent convergent adaptation to the selective pressures of the AD skin environment and help identify bacterial functions relevant to persistence or pathogenicity.
Context and caution:
This is a conceptual paper rather than a new clinical or experimental study. Its interest lies in shifting the microbiome discussion from static descriptions of dysbiosis toward microbial evolution within individual patients. Convergent mutations do not automatically prove that a variant confers a clinically important advantage; functional genetics will be required to distinguish true adaptation from neutral genomic change.
Bottom line:
AD may shape its microbes just as microbes shape AD. Viewing S. aureus through an evolutionary lens could help move the field beyond abundance and colonization toward understanding how the chronic inflammatory environment selects bacterial traits that favour persistence, host interaction and possibly disease amplification.
-
What can rural and urban AmaXhosa children teach us about AD susceptibility?
Zhakparov D et al. PLOS Medicine, 2026.
➜ DOI: 10.1371/journal.pmed.1004917
Why it matters:
Most molecular AD studies come from European, North American or Asian populations. This study examines 217 AmaXhosa children in South Africa, a population in which children sharing a common ethnogenetic background experience markedly different rural and urban environments. Using explainable machine learning to integrate environmental exposures, cytokines, allergen-specific antibodies and transcriptomics, the investigators identified one multimodal cluster associated with the healthy phenotype and two clusters associated with AD. The healthy cluster contained predominantly rural environmental features linked to cytokine patterns and expression of autophagy-related genes, while susceptibility clusters incorporated IgE, MCP-4/TARC and an AD-associated transcriptomic signature.
Context and caution:
The strength of the work is not simply the use of machine learning but the integration of environment, immunity and gene expression in an underrepresented African population. However, “protective cluster” should not be interpreted as evidence that rural exposure itself prevents AD. This is an exploratory observational re-analysis, and the authors emphasize the absence of an independent validation cohort.
Bottom line:
Rather than searching for a single environmental or immunological determinant of AD, this study supports a multidimensional view of susceptibility and protection. It also reminds us that mechanisms derived predominantly from high-income urban populations may capture only part of global AD biology. Environmentally contrasting populations may provide particularly valuable clues to prevention.